All In Biotech

NDA 021201 · Chemisch Fbrk Krsslr

Asclera

Polidocanol · Intravenous · Sclerosing Agent

Novel

Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Mar 30, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

42

7 Phase 3, 4 recruiting

FAERS reports

450

263 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 16, 2025.

Asclera ® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. Asclera (polidocanol) is a sclerosing agent indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3mm in diameter. ( 1 )

Mechanism: The active ingredient of Asclera is polidocanol. Polidocanol is a sclerosing agent that locally damages the endothelium of blood vessels. When injected intravenously, polidocanol induces endothelial damage. Platelets then aggregate at the site of damage and attach to the venous wall. Eventually, a dense network of platelets, cellular debris, and fibrin occludes the vessel. Finally, the occluded vein is replaced with connective fibrous tissue.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ASCLERA · POLIDOCANOL 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ASCLERA · POLIDOCANOL 20MG/2ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Polidocanol" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • deep vein thrombosis35
  • pain28
  • pruritus28
  • off label use27
  • erythema26
  • dizziness24
  • swelling24
  • injection site pain23
  • pain in extremity23
  • nausea22
  • urticaria22
  • drug ineffective20

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20081
20092
20114
20126
201321
20146
201519
201634
201748
201864
201928
202043
202127
202246
202319
202418
202524
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 228 on PubMed

Sponsor: Chemisch Fbrk Krsslr

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.